

Ref: EPL/CS/SE/0070/2026**Date:** August 07, 2026

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051	BSE Limited P J Towers, Dalal Street, Mumbai- 400 001
Script Symbol: EMCURE	Scrip Code/Symbol: 544210/ EMCURE

Dear Sir/Madam,

Subject: Newspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Unaudited Financial Results of the Company for the quarter ended June 30, 2026, as published in the newspapers viz. "Financial Express" and "Loksatta" on August 07, 2026.

The above-mentioned extracts of Newspaper Publication are also being uploaded on the website of the Company i.e. www.emcure.com.

You are requested to take the above information on your records.

Thanking you,

For **Emcure Pharmaceuticals Limited**

Amruta Yungalwar
Company Secretary & Compliance Officer
ICSI Membership Number: A25687

Emcure Pharmaceuticals Limited

Registered Office: Plot No. P-1 & P-2, IT-BT Park, Phase-II, M.I.D.C., Hinjawadi, Pune - 411057, Maharashtra, India
Phone Nos.: +91 20 – 35070033/ 35070000 **Fax No.:** +91 20 3507 0060
E-mail: corporate@emcure.com **Website:** www.emcure.com **CIN:** L24231PN1981PLC024251

Emcure®

EMCURE PHARMACEUTICALS LIMITED

Registered and Corporate Office: Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune - 411 057, Maharashtra, India.

Tel: +91 20 3507 0033, +91 20 3507 0000; E-mail: investors@emcure.com; Website: www.emcure.com

Corporate Identity Number: L24231PN1981PLC024251

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(₹ in million)

Sr. No.	Particulars	Quarter ended			Year ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
1	Total Revenue from operations	25,804.47	24,697.03	21,005.37	92,035.40
2	Net Profit before tax	3,935.26	3,411.76	2,907.58	12,871.43
3	Net Profit after tax	2,924.93	2,437.36	2,147.93	9,412.69
4	Total Comprehensive Income	3,131.64	2,767.74	2,943.67	11,073.91
5	Paid up equity share capital [Face value per share: ₹ 10]	1,896.82	1,895.90	1,895.08	1,895.90
6	Other equity (as shown in the audited Balance Sheet)				47,604.42
7	Earnings per share (not annualised for the Quarter ended):				
	Basic (in ₹)	15.50	12.84	10.92	48.77
	Diluted (in ₹)	15.50	12.84	10.92	48.77

The key information of the Standalone Financial results of the Company are given below:

(₹ in million)

Sr. No.	Particulars	Quarter ended			Year ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
1	Total Revenue from operations	14,509.31	14,677.03	10,965.73	52,431.88
2	Net Profit before tax	2,686.73	3,062.66	1,656.69	9,441.91
3	Net Profit after tax	2,001.08	2,336.97	1,227.89	7,329.59
4	Total Comprehensive Income	1,999.95	2,350.21	1,225.65	7,336.09

Notes:

- The above Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 06, 2026.
- The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange websites, www.bseindia.com and www.nseindia.com and on the Company's website www.emcure.com.



Place: Pune
Date: 06 August 2026

For EMCURE PHARMACEUTICALS LIMITED

Sd/-
Satish Mehta
Managing Director & CEO
DIN: 00118691

Adfactors 241/26

Emcure[®]

EMCURE PHARMACEUTICALS LIMITED

Registered and Corporate Office: Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune - 411 057, Maharashtra, India.

Tel: +91 20 3507 0033, +91 20 3507 0000; E-mail: investors@emcure.com; Website: www.emcure.com

Corporate Identity Number: L24231PN1981PLC024251

EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026

(₹ in million)

Sr. No.	Particulars	Quarter ended			Year ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
1	Total Revenue from operations	25,804.47	24,697.03	21,005.37	92,035.40
2	Net Profit before tax	3,935.26	3,411.76	2,907.58	12,871.43
3	Net Profit after tax	2,924.93	2,437.36	2,147.93	9,412.69
4	Total Comprehensive Income	3,131.64	2,767.74	2,943.67	11,073.91
5	Paid up equity share capital [Face value per share: ₹ 10]	1,896.82	1,895.90	1,895.08	1,895.90
6	Other equity (as shown in the audited Balance Sheet)				47,604.42
7	Earnings per share (not annualised for the Quarter ended):				
	Basic (in ₹)	15.50	12.84	10.92	48.77
	Diluted (in ₹)	15.50	12.84	10.92	48.77

The key information of the Standalone Financial results of the Company are given below:

(₹ in million)

Sr. No.	Particulars	Quarter ended			Year ended
		30-Jun-26	31-Mar-26	30-Jun-25	31-Mar-26
1	Total Revenue from operations	14,509.31	14,677.03	10,965.73	52,431.88
2	Net Profit before tax	2,686.73	3,062.66	1,656.69	9,441.91
3	Net Profit after tax	2,001.08	2,336.97	1,227.89	7,329.59
4	Total Comprehensive Income	1,999.95	2,350.21	1,225.65	7,336.09

Notes:

- The above Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on August 06, 2026.
- The above is an extract of the detailed format of the Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 filed with the Stock Exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of these Financial Results are available on the Stock Exchange websites, www.bseindia.com and www.nseindia.com and on the Company's website www.emcure.com.



For EMCURE PHARMACEUTICALS LIMITED

Place: Pune
Date: 06 August 2026

Sd/-
Satish Mehta
Managing Director & CEO
DIN: 00118691